BridgeBio Pharma, Inc. (BBIO) is a Biotechnology company in the Healthcare sector, currently trading at $77.70. It has a SharesGrow Score of 53/100, indicating a mixed investment profile with 3 out of 7 criteria passed.
Analyst consensus target is BBIO = $100 (+28.5% upside).
Valuation: BBIO trades at a trailing Price-to-Earnings (P/E) of -20.1 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.15.
Financials: revenue is $502M, +774.5%/yr average growth. Net income is $729M (loss), growing at -16.5%/yr. Net profit margin is -145.3% (negative). Gross margin is 94.4% (-1.2 pp trend).
Balance sheet: total debt is $2.7B with negative equity of -$2.1B — this means total liabilities exceed total assets. This is a warning sign that may indicate accumulated losses, aggressive share buybacks, heavy debt financing, or aggressive dividend payouts. Companies like McDonald's and Starbucks also carry negative equity due to buybacks and dividends, but investors should assess whether the business generates sufficient cash flow to service its debt and sustain payouts. Current ratio is 2.62 (strong liquidity). Debt-to-assets is 291.5%. Total assets: $936M.
Analyst outlook: 25 / 26 analysts rate BBIO as buy (96%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 90/100 (Pass), Growth 58/100 (Partial), Past 0/100 (Fail), Health 50/100 (Partial), Moat 72/100 (Pass), Future 94/100 (Pass), Income 10/100 (Fail).
